SAB Biotherapeutics (NASDAQ:SABS) Price Target Raised to $14.00

SAB Biotherapeutics (NASDAQ:SABS) had its target price raised by Chardan Capital from $12.00 to $14.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also issued reports on SABS. Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Guggenheim initiated coverage on SAB Biotherapeutics in a report on Friday, December 19th. They set a “buy” rating and a $15.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. UBS Group assumed coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price for the company. Finally, HC Wainwright reduced their target price on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $4.15 on Wednesday. The company’s fifty day moving average is $4.02 and its two-hundred day moving average is $3.36. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 10.50. The firm has a market capitalization of $211.44 million, a price-to-earnings ratio of -1.79 and a beta of 0.59.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). Equities research analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Large investors have recently modified their holdings of the stock. HB Wealth Management LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter worth approximately $618,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at $32,000. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at $30,000. Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the third quarter valued at $40,000. Finally, Commodore Capital LP bought a new stake in SAB Biotherapeutics in the third quarter valued at $8,847,000. 7.82% of the stock is currently owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.